PharmaCyte Biotech reports FY2022 net loss of $4.2M; cash at $85.4M; authorizes $10M buyback

PharmaCyte Biotech, Inc.

Cash and cash equivalents of $85.4M as of April 30, 2022; no debt mentioned.
Net loss of ~$4.2M ($0.27 per share) compared to net loss of $3.6M ($2.45 per share) in prior year.
Operating expenses increased to ~$4.4M from $3.6M, mainly due to Nasdaq listing and $90M capital raises.
Board authorized up to $10M share repurchase program, to begin after release of preliminary results.
CEO says company expects to begin two-phase pig study, the last major FDA requirement for phase 2b LAPC trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.